A highly potent, long-acting drug candidate with a novel mode of action showed promising anti-HIV activity in recent phase 1 trials. The slow-release compound, lenacapavir (previously GS-6207), would be used in combination with other antiretroviral agents, researchers said at the 23rd International AIDS Conference.
Abbasi J. Promising Early Results for Potent, Long-Acting HIV Injection. JAMA. 2020;324(6):539. doi:10.1001/jama.2020.14031
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: